

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A ~~venlafaxin~~ containing coated tablet with controlled release, ~~characterized in that it contains~~ wherein the coated tablet comprises venlafaxin, or its salt with an inorganic or carboxylic acid, in amounts from 20 to 60 weight %, and a hydrophilic polymer in amounts from 30 up to 70 weight %, based on the weight of the core, in its core, and from 1 up to 3 weight % of a water-poorly permeable or impermeable polymer in its coating.

Claim 2 (Currently Amended): The coated tablet according to claim 1, ~~characterized in that its~~ wherein the total weight of the coated tablet does not exceed 500 mg.

Claim 3 (Currently Amended): The coated tablet according to claim 1 ~~or 2~~, ~~characterized in that it contains a cellulose ester as~~ wherein the hydrophilic polymer comprises a cellulose ester in the core.

Claim 4 (Currently Amended): The coated tablet of claim 1 according to any of claims 1 to 3, wherein the coated tablet comprises the water-poorly permeable polymer, and wherein the water-poorly permeable polymer comprises an acrylic polymer characterized in that it contains an acrylic polymer as the water-poorly permeable polymer in the coating.

Claim 5 (Currently Amended): The coated tablet of claim 1 according to any of claims 1 to 4, characterized in that it contains wherein the coated tablet comprises 75 mg of the active substance, based on the venlafaxin base, from 100 to 200 mg of Methocel K 100M Premium EP in its core and from 3 to 10 mg of Eudragit L 30 D-55 in its coating.

Claim 6 (Currently Amended): The coated tablet of claim 1 according to any of the claims 1 to 4, characterized in that it contains wherein the coated tablet comprises 150 mg of the active substance, based on the venlafaxin base, from 150 to 300 mg of Methocel K 100M Premium EP in its core and from 3 to 10 mg of Eudragit L 30 D in its coating.

Claim 7 (Currently Amended): A method of production of the tablet according to claim 1, characterized in that a comprising

mixing a mixture of venlafaxin and a hydrophilic polymer is mixed in a homogenizing device, with optional optionally, subsequently adding subsequent addition of colloidal silicon dioxide along with magnesium stearate,

homogenizing the mixture to form a blend,

briquetting the blend to form a tablet material which comprises a particle size,

adjusting the particle size of the tablet material,

compressing the tablet material into tablets, and

coating the tablets with a suspension,

wherein the suspension comprises the water-poorly permeable polymer and,

optionally, talc and acetyl triethyl citrate

~~after homogenizing the mixture is briquetted, subsequently the particle size of the tablet material is adjusted and compressing into tablets is carried, the tablets being coated with a suspension of the water-poorly permeable polymer, optionally along with talc and acetyl triethyl citrate.~~

Claim 8 (New): The coated tablet of claim 1, wherein the coated tablet comprises, in its coating, the water-poorly permeable polymer.

Claim 9 (New): The coated tablet of claim 1, wherein the coated tablet comprises, in its coating, the impermeable polymer.

Claim 10 (New): The method of claim 7, wherein the colloidal silicon dioxide along with magnesium state are subsequently added.

Claim 11 (New): The method of claim 7, wherein the suspension comprises the water-poorly permeable polymer, talc, and triethyl citrate.

Claim 12 (New): The coated tablet of claim 2, wherein the hydrophilic polymer comprises a cellulose ester.

Claim 13 (New): The coated tablet of claim 2, wherein the coated tablet comprises the water-poorly permeable polymer, and wherein the water-poorly permeable polymer comprises an acrylic polymer.

Claim 14 (New): The coated tablet of claim 3, wherein the coated tablet comprises the water-poorly permeable polymer, and wherein the water-poorly permeable polymer comprises an acrylic polymer.

Claim 15 (New): The coated tablet of claim 2, wherein the coated tablet comprises 75 mg of the active substance, based on the venlafaxin base, from 100 to 200 mg of Methocel K 100M Premium EP in its core and from 3 to 10 mg of Eudragit L 30 D-55 in its coating.

Claim 16 (New): The coated tablet of claim 3, wherein the coated tablet comprises 75 mg of the active substance, based on the venlafaxin base, from 100 to 200 mg of Methocel K 100M Premium EP in its core and from 3 to 10 mg of Eudragit L 30 D-55 in its coating.

Claim 17 (New): The coated tablet of claim 4, wherein the coated tablet comprises 75 mg of the active substance, based on the venlafaxin base, from 100 to 200 mg of Methocel K 100M Premium EP in its core and from 3 to 10 mg of Eudragit L 30 D-55 in its coating.

Claim 18 (New): The coated tablet of claim 2, wherein the coated tablet comprises 150 mg of the active substance, based on the venlafaxin base, from 150 to 300 mg of Methocel K 100M Premium EP in its core and from 3 to 10 mg of Eudragit L 30 D in its coating.

Claim 19 (New): The coated tablet of claim 3, wherein the coated tablet comprises 150 mg of the active substance, based on the venlafaxin base, from 150 to 300 mg of Methocel K 100M Premium EP in its core and from 3 to 10 mg of Eudragit L 30 D in its coating.

Claim 20 (New): The coated tablet of claim 4, wherein the coated tablet comprises 150 mg of the active substance, based on the venlafaxin base, from 150 to 300 mg of

Docket No. 291335US0PCT
Preliminary Amendment

Methocel K 100M Premium EP in its core and from 3 to 10 mg of Eudragit L 30 D in its coating.